Enlivex Therapeutics Ltd.
NASDAQ:ENLV
1.08 (USD) • At close February 4, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 2.277 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.835 | 0.777 | 0.546 | 0.286 | 0.297 | 0.121 | 0.012 | 0.025 | 0.017 | 0 | 0 | 0 |
| Gross Profit
| -0.835 | -0.777 | -0.546 | 1.991 | -0.297 | -0.121 | -0.012 | -0.025 | -0.017 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 0.874 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 19.235 | 18.693 | 12.881 | 6.086 | 5.724 | 4.255 | 2.517 | 8.881 | 7.694 | 4.441 | 0.732 | 0.14 |
| General & Administrative Expenses
| 6.139 | 6.702 | 6.24 | 3.602 | 2.75 | 0.937 | 2.959 | 6.985 | 6.953 | 2.639 | 0.416 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0.479 | 0 | 0.829 | 0 | 0 | 0 |
| SG&A
| 6.139 | 6.702 | 6.24 | 3.602 | 2.75 | 0.937 | 3.438 | 6.985 | 7.782 | 2.639 | 0.416 | 0.086 |
| Other Expenses
| 4.021 | 0.402 | 0.167 | 0.097 | 0.145 | 0 | 0 | 0 | -0.829 | 0 | 0 | 0 |
| Operating Expenses
| 29.395 | 25.797 | 19.288 | 9.785 | 8.619 | 5.299 | 5.955 | 15.866 | 15.476 | 7.08 | 1.148 | 0.226 |
| Operating Income
| -29.395 | -25.797 | -19.288 | -9.785 | -8.619 | -5.299 | -5.955 | -15.866 | -15.476 | -7.08 | -1.148 | -0.226 |
| Operating Income Ratio
| 0 | 0 | 0 | -4.297 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 0.327 | -5.263 | 4.82 | -2.039 | -0.765 | 1.057 | -0.067 | -1.86 | 0.135 | 0.058 | 0.003 | -0.003 |
| Income Before Tax
| -29.068 | -31.06 | -14.468 | -11.824 | -9.384 | -4.242 | -5.917 | -15.806 | -15.341 | -7.022 | -1.145 | -0.229 |
| Income Before Tax Ratio
| 0 | 0 | 0 | -5.193 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 11.347 | -4.82 | 2.039 | 0.765 | 1.057 | 0.028 | 0.216 | 0.024 | 0 | 0.002 | 0 |
| Net Income
| -29.068 | -42.407 | -9.648 | -13.863 | -10.149 | -4.242 | -5.945 | -16.022 | -15.365 | -7.022 | -1.145 | -0.229 |
| Net Income Ratio
| 0 | 0 | 0 | -6.088 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.56 | -2.31 | -0.54 | -1.05 | -1.17 | -1.21 | -14.35 | -40.29 | -43.19 | -22.91 | -4.21 | -0.84 |
| EPS Diluted
| -1.56 | -2.31 | -0.54 | -1.05 | -1.17 | -1.21 | -13.88 | -40.29 | -43.19 | -22.91 | -4.21 | -0.84 |
| EBITDA
| -28.219 | -25.02 | -18.742 | -9.499 | -9.08 | -5.178 | -5.905 | -15.781 | -15.312 | -7.075 | -1.143 | -0.226 |
| EBITDA Ratio
| 0 | 0 | 0 | -3.18 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |